Salvatore Iacono, Vincenzo Di Stefano, Paolo Alonge, Claudia Vinciguerra, Giammarco Milella, Francesca Caputo, Piergiorgio Lasorella, Gabriele Neto, Antonia Pignolo, Angelo Torrente, Antonino Lupica, Paola Ajdinaj, Alberto Firenze, Stefano Tozza, Fiore Manganelli, Antonio Di Muzio, Giuseppe Piscosquito, Filippo Brighina
BACKGROUND: The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy. METHODS: A multicentric and web-based cross-sectional survey was conducted among patients affected by neuropathy from part of South Italy. RESULTS: Out of 285 responders, n = 268 were included in the final analysis and n = 258 of them (96...
October 16, 2022: Brain Sciences